CryoLife (CRY) Receives Daily News Impact Rating of 0.11

News coverage about CryoLife (NYSE:CRY) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CryoLife earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 48.0670900807073 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

CryoLife (CRY) traded down $0.55 on Friday, hitting $19.80. The stock had a trading volume of 162,760 shares, compared to its average volume of 110,526. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90. CryoLife has a twelve month low of $14.02 and a twelve month high of $24.00. The firm has a market capitalization of $662.47, a PE ratio of 48.29 and a beta of 0.81.

CryoLife (NYSE:CRY) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The business had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.60 million. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The business’s revenue was down 2.9% compared to the same quarter last year. equities research analysts forecast that CryoLife will post 0.28 earnings per share for the current fiscal year.

CRY has been the topic of a number of analyst reports. Lake Street Capital raised their price target on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research cut CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Northland Securities restated a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research note on Monday, November 13th. Finally, Canaccord Genuity restated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research note on Monday, October 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $23.63.

In related news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the transaction, the chief accounting officer now owns 98,705 shares in the company, valued at approximately $1,875,395. The disclosure for this sale can be found here. Insiders have sold 229,240 shares of company stock worth $4,888,065 in the last quarter. Insiders own 6.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CryoLife (CRY) Receives Daily News Impact Rating of 0.11” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit